P1/2, N=52, Terminated, Numab Therapeutics AG | N=406 --> 52 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Feb 2024; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

9 months ago

Enrollment change • Trial termination • Trial primary completion date • Trispecific • Metastases

NM21-1480

11ms

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=406, Active, not recruiting, Numab Therapeutics AG

11 months ago

Trial completion date • Trispecific • Metastases

NM21-1480

12ms

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=406, Active, not recruiting, Numab Therapeutics AG | Recruiting --> Active, not recruiting

12 months ago

Enrollment closed • Trispecific • Metastases

NM21-1480

over1year

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin. (PubMed, Oncoimmunology)

In xenograft models, NM28-2746 exhibited significant tumor suppressing activity, which was significantly enhanced by combination therapy with NM21-1480. NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN.

over 1 year ago

Journal • PD(L)-1 Biomarker • IO biomarker

MSLN (Mesothelin)

MSLN expression

NM21-1480 • NM28-2746